At 17.0% CAGR, the Asia Pacific T Cell Therapy Market is Projected to be Worth US$ 882.72 million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific T cell therapy market was valued at US$ 251.99 million in 2022 and is expected to reach US$ 882.72 million by 2030, registering a CAGR of 17.0% from 2022 to 2030. Growing burden of cancer worldwide and increasing number of approvals of t-cell therapies are among the critical factors attributed to the Asia Pacific T cell therapy market expansion.             

The current landscape for CAR T-cell therapies across the globe is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Pipelines of CAR T-cell therapies are in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T-cell therapy competitive domain.

In November 2022, Peter MacCallum Cancer Centre and Cartherics Pty Ltd entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR T cell therapy (CTH-001) for treating cutaneous T-cell lymphoma (CTCL). The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. It will initially enroll six patients with refractory CTCL. JW Therapeutics drug JWCAR029 is a CAR T cell product that targets CD19 and is intended to treat advanced lymphoma and leukemia. The molecule is currently in Phase II of development. JWCAR029 is initially being investigated for treating B-cell malignancies, focusing on relapsed and refractory DLBCL. Gilead Sciences drug KTE-X19 is an autologous CD19 CAR T-cell therapy under investigation. The drug is manufactured using the XLP process, including T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is required in certain B-cell malignancies for which KTE-X19 is being studied. KTE-X19 is currently in Phase II clinical trials for the treatment of both adult and pediatric acute lymphocytic leukemia. The FDA has approved Brexucabtagene autoleucel (formerly KTE-X19; Tecartus) for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL). ZUMA-3 is a Phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Descartes-11, a mRNA CAR T-cell therapy, has moved into a Phase II clinical trial for newly diagnosed, high-risk multiple myeloma (MM) patients. Descartes-11 expresses CAR T-cell molecules transiently and avoids some characteristic toxicities of these therapeutic agents. A Phase I study (NCT03994705) of 18 patients has already been undertaken, and results showed no evidence of cytokine release syndrome or neurotoxicity—adverse events commonly associated with CAR T-cell treatment. Thus, the pipelines above for CAR T-cell therapies are emerging as a new trend in the Asia Pacific T-cell therapy market.

On the contrary, side-effects of CAR T-cell therapy hampers on the growth of Asia Pacific T cell therapy market. 

Based on modality, the Asia Pacific T cell therapy market is bifurcated into research and commercialized. The commercialized segment held 89.8% market share in 2022, amassing US$  226.31 million. It is projected to garner US$ 810.34 million by 2030 to expand at 17.3% CAGR during 2022–2030.

Based on therapy type, the Asia Pacific T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held 99.7% share of Asia Pacific T cell therapy market in 2022, amassing US$ 251.23 million. It is projected to garner US$ 881.54 million by 2030 to expand at 17.0% CAGR during 2022–2030.

Based on indication, the Asia Pacific T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held 99.7% share of Asia Pacific T cell therapy market in 2022, amassing US$ 251.23 million. It is projected to garner US$ 881.54 million by 2030 to expand at 17.0% CAGR during 2022–2030.

Based on country, the Asia Pacific T cell therapy market has been categorized into China, Japan, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 36.0% share of Asia Pacific T cell therapy market in 2022. It was assessed at US$ 90.66 million in 2022 and is likely to hit US$ 329.83 million by 2030, exhibiting a CAGR of 17.5% during 2022–2030.            

Key players operating in the Asia Pacific T cell therapy market are Bristol-Myers Squibb Co, Gilead Sciences Inc, Innovent Biologics Inc, Janssen Global Services LLC, JW (Cayman) Therapeutics Co Ltd, Legend Biotech Corp, and Novartis AG, among others.

• May 2023: Janssen Biotech, Inc. has collaborated with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies. These investigational CD20-directed autologous CAR-Ts have demonstrated promising overall and complete response rates in Phase 1 studies in patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL) in China, with the majority of study participants having diffuse large B-cell lymphoma (DLBCL), the most common type of aggressive lymphoma accounting for approximately one-third of B-cell lymphomas globally.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com